View this email in your browser
In this Issue
CMS Issues P-Codes for Hospital OPPS Reimbursement  of Pathogen Reduced Platelets and Plasma | OneBlood, Inc. Signs INTERCEPT Agreement | CBCC to Adopt INTERCEPT ABC Survey AABB Poster | AABB PR Symposium Video | Science Section: What We're Reading | Calendar of Events
CMS Issues P-Codes for Hospital Outpatient Billing of PR Platelets and Plasma
The Centers for Medicare & Medicaid Services (CMS) recently released 2016 payment rates paid under the outpatient prospective payment system (OPPS). Included in the final rule are approved permanent, Level II Healthcare Common Procedure Coding System (HCPCS) billing codes that will allow hospitals to bill and secure reimbursement for pathogen reduced (PR) platelet and plasma components in the outpatient setting. Most notably, the rate for a PR platelet unit reflects a premium of $153.56 over the rate for a unit of conventional apheresis platelets.
New CY 2016
New HCPCS P-Code
Long Descriptor
Final CY 2016 OPPS Payment Amount
P9070 Plasma, pooled multiple donor, pathogen reduced, frozen, each unit $73.08
P9071 Plasma (single donor), pathogen reduced, frozen, each unit $72.56
P9072 Platelets, pheresis, pathogen reduced, each unit $641.85

The INTERCEPT Blood System is currently the only FDA-approved system for pathogen reduction of platelet and plasma components, designed to reduce the risk of transfusion-transmitted infections.
For more information regarding the Hospital OPPS final rule, please visit the CMS website.

OneBlood, Inc. Enters into Agreement to Adopt the INTERCEPT Blood System
The nations third largest blood product supplier, OneBlood, Inc., has entered into a mutli-year purchase agreement for the INTERCEPT Blood System for Platelets and Plasma. “Safety of the blood supply is OneBlood’s top priority,” said Don Doddridge president and chief executive officer of OneBlood. “The INTERCEPT pathogen reduction system provides an additional layer of safety to our existing testing processes and enables us to deploy cutting-edge pathogen reduction technology to further ensure safe blood for our hospital partners and their patients.”

OneBlood distributes approximately one million blood products to more than 200 hospitals and healthcare facilities throughout most of Florida, parts of Southern Georgia, Alabama, and South Carolina. To learn more about OneBlood, please visit

CBCC to Adopt the INTERCEPT Blood System
Cerus and the Community Blood Center of the Carolinas (CBCC) have recently entered into a three-year agreement for the INTERCEPT Blood System for Platelets and Plasma.“Our goal is to provide blood components of the highest possible level of quality and safety for the hospitals and patients we serve” said Martin Grable, CBCC’s president and chief executive officer. “INTERCEPT-treated platelets and plasma enable us to offer an even safer choice of blood components in the Carolinas.”  CBCC provides over 12,000 platelet and 22,000 plasma units annually to 27 regional hospitals.
To learn more about CBCC, please visit

AABB Poster Highlights Disconnect in PR Platelet Adoption Perceptions between Blood Centers and Hospitals (SP309 Katz, L et al.)
Results of an online survey that evaluated perceptions about pathogen-reduced platelets – including general awareness, ability to avoid bacterial testing, and pricing perceptions,– were presented during the recent 2015 AABB Annual Meeting in Anaheim, California. Data from the 49 blood center and 243 hospital respondents reflect significant differences in perceptions related to PR drivers and deterrents, awareness of existing risks, and hospital pricing increase tolerance.
Read the full abstract (open access).

Pathogen Reduction in Practice – US Blood Center and Hospital Perspectives: Symposium Video Coming Soon
During the recent AABB Annual Meeting, Cerus hosted a corporate symposium discussing the increasing adoption momentum for the INTERCEPT Blood System in the United States. Speakers included Drs. Richard J. Benjamin, James P. AuBuchon and Joanne Becker; Drs., James R. Stubbs and Patricia Kopko joining the panel discussion. Presentations and related discusses addressed the current landscape of blood safety and transfusion medicine, blood center and hospital approaches to pathogen reduction adoption, as well as the value that INTERCEPT-treated components may provide to patients.

The symposium video will be made available, later this month on

Science Section: What We're Reading

Fatal False-Negative Transfusion Infection Involving a Buffy Coat Platelet Pool Contaminated with Biofilm-Positive Staphylococcus epidermidis: A Case Report
Kou, Y et al. Transfusion. 2015 Oct;55(10):2384-9.

Transfusion-Transmitted Babesiosis During Total Hip Arthroplasty
Carnevale, BA et al. Orthopedics. 2015 Sep 1;38(9):e852-5.

Seroprevalence of Babesia microti Infection in Canadian Blood Donors
O’Brien SF, et al. Transfusion. Oct 1 doi:10.1111/trf.13339. [Epub ahead of print]

Implementation of a Novel Real-Time Platelet Inventory Management System at a Multi-Site Transfusion Service
Gomez, AT et al. Transfusion. 2015 Sep;55(9):2070-5.

Calendar of Events
 ISBT Regional Conference | November 14-16, 2015 | Bali, Indonesia
There is no pathogen inactivation process that has been shown to eliminate all pathogens. Certain non-enveloped viruses (e.g., HAV, HEV, B19 and poliovirus) and Bacillus cereus spores have demonstrated resistance to the INTERCEPT process.

CONTRAINDICATIONS: Contraindicated for preparation of plasma and platelet components intended for patients with a history of hypersensitivity reaction to amotosalen or other psoralens. Contraindicated for preparation of platelet and plasma components intended for neonatal patients treated with phototherapy devices that emit a peak energy wavelength less than 425 nm, or have a lower bound of the emission bandwidth <375 nm, due to the potential for erythema resulting from interaction between ultraviolet light and amotosalen.

WARNINGS and PRECAUTIONS: Only INTERCEPT Processing Sets for platelets and plasma are approved for use with the INTERCEPT Blood System. Use only the INTERCEPT INT100 Illuminator for UVA illumination of amotosalen-treated platelet and plasma components. No other source of UVA light may be used. Please refer to the Operator's Manual for the INT100 Illuminator. Discard any platelet or plasma components not exposed to the complete INT100 illumination process. Tubing components and container ports of the INTERCEPT Blood System contain polyvinyl chloride (PVC). Di(2-ethylhexyl) phthalate (DEHP) is known to be released from PVC medical devices, and increased leaching can occur with extended storage or increased surface area contact. Blood components will be in contact with PVC for a brief period of time (approx. 15 minutes) during processing. The risks associated with DEHP released into the blood components must be weighed against the benefits of therapeutic transfusion.

PLATELETS: INTERCEPT processed platelets may cause the following adverse reaction: Acute Respiratory Distress Syndrome (ARDS). An increased incidence of ARDS was reported in a randomized trial for recipients of INTERCEPT processed platelets, 5/318 (1.6%), compared to recipients of conventional platelet components (0/327). Monitor patients for signs and symptoms of ARDS.

PLASMA: Amotosalen-treated plasma may cause the following adverse reaction Cardiac Events. In a randomized controlled trial of therapeutic plasma exchange (TPE) for TTP, five patients treated with INTERCEPT Blood System processed plasma and none with conventional plasma had adverse events in the cardiac system organ class (SOC) reported. These events included angina pectoris (n=3), cardiac arrest (n=1), bradycardia (n=1), tachycardia (n=1) and sinus arrhythmia (n=1). None of these events resulted in documented myocardial infarction or death. Monitor patients for signs and symptoms of cardiac events during TPE for TTP.

Rx only. For full prescribing information, please see package insert.
Copyright © 2015 Cerus Corporation, All rights reserved.

unsubscribe from this list    update subscription preferences